STOCK TITAN

BioNTech SE American Depositary Share - BNTX STOCK NEWS

Welcome to our dedicated page for BioNTech SE American Depositary Share news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE American Depositary Share stock.

BioNTech SE (American Depositary Share - BNTX) is a leading biotechnology company based in Germany, renowned for its pioneering work in the field of immunotherapy and vaccines. BioNTech's core business revolves around developing innovative cancer treatments and vaccines for infectious diseases, including the widely recognized COVID-19 vaccine, Comirnaty, which it co-developed with Pfizer.

BioNTech's oncology pipeline encompasses several advanced drug classes, including mRNA-based drugs that encode antigens, neoantigens, cytokines, and antibodies. The company is also advancing cell therapies, bispecific antibodies, and antibody-drug conjugates, positioning itself at the forefront of cancer treatment innovation.

Partnerships play a crucial role in BioNTech's strategy. The company collaborates with major pharmaceutical giants such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, leveraging shared expertise to accelerate the development and commercialization of its therapies. Recent strategic collaborations include an agreement with MediLink Therapeutics to utilize their TMALIN® antibody-drug conjugate platform, enhancing BioNTech's capabilities in targeting novel cancer therapeutics.

BioNTech's financial health is robust, bolstered by the commercial success of Comirnaty and ongoing strategic partnerships. The company's commitment to innovation and excellence is reflected in its continuous efforts to develop new therapeutics and vaccines, ensuring significant contributions to global healthcare.

For more detailed information, visit the company's official website at www.BioNTech.com.

Rhea-AI Summary

On September 17, 2021, Pfizer and BioNTech announced that the FDA's VRBPAC unanimously recommended Emergency Use Authorization for a COMIRNATY booster dose for individuals 65 and older, and those at high risk of severe COVID-19. The booster, six months post the two-dose series, shows robust neutralization against SARS-CoV-2 and variants. Real-world data from Israel indicates significant protection levels comparable to early vaccine rollout. The FDA decision is pending, which could make COMIRNATY the first authorized COVID-19 vaccine booster in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

The FDA's Vaccines Advisory Committee has unanimously recommended the Emergency Use Authorization (EUA) for a COMIRNATY booster dose for individuals 65 and older and those at high risk for severe COVID-19. Data presented showed high neutralization titers against SARS-CoV-2 variants post-booster with a mild to moderate reactogenicity profile. Real-world evidence from Israel indicates that booster doses significantly enhance protection, comparable to initial vaccine effectiveness. The FDA is anticipated to make its decision soon, potentially marking COMIRNATY as the first COVID-19 booster authorized in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
none
-
Rhea-AI Summary

BioNTech SE (BNTX) announced plans to assess the establishment of sustainable vaccine manufacturing in Rwanda and Senegal. This decision, made during a meeting in Berlin with African leaders and the European Commission, aims to enhance vaccine supply for the African Union member states. BioNTech intends to produce mRNA vaccines targeting Malaria and Tuberculosis on the continent. The company is already evaluating production capabilities to align with WHO’s upcoming Vaccine Hubs, amid a wider initiative supported by European partners to increase access to vaccines in Africa.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
Rhea-AI Summary

Pfizer and BioNTech have signed a letter of intent with Eurofarma to manufacture and distribute the COMIRNATY COVID-19 vaccine in Latin America. Eurofarma will engage in manufacturing activities within Pfizer’s global supply chain, with production expected to exceed 100 million doses annually starting in 2022. This collaboration aims to enhance vaccine access across the region, complementing the companies' goal to supply over 3 billion doses globally by the end of 2021. The partnership is part of ongoing efforts to ensure equitable vaccine distribution amid the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
covid-19
-
Rhea-AI Summary

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have signed a letter of intent with Eurofarma Laboratórios SA to manufacture their COVID-19 vaccine, COMIRNATY®, for distribution in Latin America. Eurofarma will initiate technical transfer and on-site development immediately, with finished dose production expected to exceed 100 million doses annually, beginning in 2022. This collaboration aims to enhance equitable access to vaccines in the region, contributing to a total of 3 billion doses planned for global distribution by year-end 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
covid-19
-
Rhea-AI Summary

BioNTech (BNTX) announced the submission of a supplemental Biologics License Application (sBLA) for a booster dose of COMIRNATY. Phase 3 trial results show a third dose generates 3.3 times higher neutralizing antibody titers against the SARS-CoV-2 wild-type strain compared to the second dose. The safety profile is favorable, with mild to moderate side effects typical of previous doses. The companies aim to file this data with the EMA and other authorities soon. Notably, the third dose is not yet authorized for general use in the U.S., pending regulatory assessments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
Rhea-AI Summary

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced the initiation of a supplemental Biologics License Application for a third dose of COMIRNATY. New Phase 3 trial data show the booster dose significantly increases SARS-CoV-2 neutralizing antibody titers, achieving levels 3.3 times higher than the second dose. The companies plan to submit these findings to the European Medicines Agency and other regulatory bodies shortly. Adverse events observed were mild to moderate, with a low incidence of severe reactions, consistent with previous clinical data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Summary

Pfizer and BioNTech received FDA approval for COMIRNATY®, making it the first FDA-approved COVID-19 vaccine for individuals aged 16 and older. This vaccine has been available under Emergency Use Authorization since December 2020. The approval validates the vaccine's efficacy and safety, supported by long-term Phase 3 trial data. Approximately 60% of eligible Americans are fully vaccinated, and the companies aim to enhance vaccine confidence. COMIRNATY is also authorized for individuals aged 12-15 under EUA and will seek further approvals for booster doses and younger age groups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
fda approval covid-19
-
Rhea-AI Summary

COMIRNATY, the first FDA-approved COVID-19 vaccine, has been licensed for individuals aged 16 and older. The approval follows a comprehensive review of six-month efficacy and safety data post-second dose. Over 1.2 billion doses have been delivered globally since December 2020. Pfizer and BioNTech anticipate the approval will enhance public confidence in vaccinations as the U.S. grapples with rising COVID-19 rates, especially among unvaccinated populations. Moreover, plans for a third dose and expansion for younger populations are underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
fda approval covid-19
Rhea-AI Summary

Pfizer (PFE) and BioNTech (BNTX) have submitted Phase 1 data to the FDA for a booster dose of their COVID-19 vaccine (BNT162b2). This submission follows successful Phase 1 trials showing significantly higher neutralizing antibodies after a third dose compared to the two-dose schedule. The companies plan to also submit this data to the EMA and other authorities soon. Although the booster is not yet widely authorized in the U.S., it was recently approved for immunocompromised individuals. Further Phase 3 results are expected shortly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.07%
Tags
covid-19

FAQ

What is the current stock price of BioNTech SE American Depositary Share (BNTX)?

The current stock price of BioNTech SE American Depositary Share (BNTX) is $114.13 as of December 24, 2024.

What is the market cap of BioNTech SE American Depositary Share (BNTX)?

The market cap of BioNTech SE American Depositary Share (BNTX) is approximately 27.4B.

What does BioNTech SE do?

BioNTech SE is a biotechnology company focused on developing cancer immunotherapies and vaccines for infectious diseases, including COVID-19.

Where is BioNTech SE based?

BioNTech SE is based in Germany.

What is BioNTech's most well-known product?

BioNTech's most well-known product is the COVID-19 vaccine, Comirnaty, developed in collaboration with Pfizer.

Who are BioNTech's major partners?

BioNTech collaborates with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab.

What types of cancer therapies is BioNTech developing?

BioNTech is developing a variety of cancer therapies, including mRNA-based drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates.

What is the TMALIN® platform?

The TMALIN® platform is an antibody-drug conjugate technology developed by MediLink Therapeutics, used by BioNTech for cancer therapeutics.

How can investors find more information about BioNTech?

Investors can find more information on BioNTech's official website or by contacting their investor relations team.

What recent collaboration has BioNTech announced?

BioNTech recently announced a strategic collaboration with MediLink Therapeutics to use their TMALIN® antibody-drug conjugate platform for novel cancer targets.

What is BioNTech's role in the fight against COVID-19?

BioNTech developed the COVID-19 vaccine Comirnaty in collaboration with Pfizer, which has become a critical tool in combating the pandemic.

Where can I find BioNTech's latest news and updates?

BioNTech's latest news and updates can be found on their official website and through their media relations contacts.

BioNTech SE American Depositary Share

Nasdaq:BNTX

BNTX Rankings

BNTX Stock Data

27.36B
91.82M
61.66%
20.63%
1.03%
Biotechnology
Healthcare
Link
United States of America
Mainz